<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898195</url>
  </required_header>
  <id_info>
    <org_study_id>12-02165</org_study_id>
    <nct_id>NCT01898195</nct_id>
  </id_info>
  <brief_title>Improving Adherence to Smoking Cessation Medication Among PLWHA</brief_title>
  <acronym>HIV</acronym>
  <official_title>Improving Adherence to Smoking Cessation Medication Among PLWHA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Smoking rates among individuals living with HIV/AIDS range between 47% and 65%, a prevalence&#xD;
      that is roughly three times the rate of the general population. This elevated prevalence is&#xD;
      alarming given the increased likelihood of numerous adverse health outcomes experienced by&#xD;
      HIV-positive smokers. Cigarette smoking is associated with greater levels of HIV-related&#xD;
      symptom burden and appears to decrease the effectiveness of HAART as assessed by both viral&#xD;
      load and CD4 counts (Vidrine 2009, Marshall 2009, Vidrine 2007, Miguez-Burbane 2005). PLWHA&#xD;
      who smoke are also at increased risk of infections and noninfectious pulmonary complications&#xD;
      and both AIDS-associated and non-AIDS-associated malignancies compared to nonsmokers. This&#xD;
      study will refine and pilot test a theory-driven smoking cessation intervention that enhances&#xD;
      existing behavioral approaches by testing the impact of text message reminders to take&#xD;
      varenicline and the feasibility and additional impact of including adherence-focused&#xD;
      behavioral cessation counseling. The investigators propose to randomize 190 participants,&#xD;
      recruited from three HIV/AIDS clinic, to a three arm pilot study that compares: 1) Standard&#xD;
      Care (SC), 2) SC + text message reminders, and 3) SC + text message reminders + cell&#xD;
      phone-delivered adherence-focused behavioral therapy (ABT). Participants in all three arms&#xD;
      will receive varenicline for 12 weeks. The primary outcomes are adherence to varenicline and&#xD;
      biochemically validated smoking abstinence at 12 weeks and 3-month follow-up from the time of&#xD;
      study enrollment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To accomplish the study's aims the investigators propose a three phase study: PHASE 1)&#xD;
      Formative phase (n=40) to pretest text messages and to explore barriers to cessation and&#xD;
      adherence to cessation medication; PHASE 2) a Pretest phase (n=10) to test and revise the&#xD;
      intervention components and to assess design issues that may emerge, including those&#xD;
      associated with contacting subjects via cell phone, participant capacity to view text&#xD;
      messages, timing and content of text messaging, and use of the eCAPs system; and PHASE 3) a&#xD;
      Pilot randomized control trial (RCT) in which the investigators will randomize 190&#xD;
      participants, recruited at St. Luke's Roosevelt Comprehensive Care Clinics, to a three-arm&#xD;
      study that compares: 1) Standard care (SC), which includes receiving varenicline and brief&#xD;
      counseling; 2) SC + daily text messages medication reminders (TxT); or 3) SC + TxT + seven&#xD;
      sessions of cell-phone-delivered, adherence-focused behavioral therapy (ABT). Text messages&#xD;
      will include medication reminders and motivational messages related to adherence and&#xD;
      maintaining abstinence. Participants in all three arms will receive varenicline for 12 weeks.&#xD;
      To have a total sample of 150 subjects through the end of treatment at 12 weeks, or 50&#xD;
      subjects in each arm, the investigators will randomize 190 patients to account for a 20%&#xD;
      attrition rate. Subjects will be surveyed at six time points including the baseline&#xD;
      assessment.&#xD;
&#xD;
      PHASE 1: FORMATIVE EVALUATION Focus groups with patients. Focus groups (lasting from 60 to 90&#xD;
      minutes) will be conducted with HIV+ smokers. To recruit patients for Phase 1, research&#xD;
      assistants will approach all individuals within the clinic setting to screen for tobacco use.&#xD;
      If they are a current smoker they will be asked if they wish to participate in a scheduled&#xD;
      focus group at a convenient time. The research assistants will recruit 80 patients and expect&#xD;
      to complete 4 focus groups with 10 participants in each for a total of 40 participants. The&#xD;
      main aims of these focus groups are: 1) to obtain feedback on the text message library to&#xD;
      determine which messages will be most acceptable and useful, and how often the patients would&#xD;
      like to receive messages; 2) to assess comfort with using the pre-paid phone to receive and&#xD;
      send messages; 3) to assess confidentiality concerns regarding receiving the text messages&#xD;
      and how the patients may be edited to avoid loss of confidentiality; and 4) to explore&#xD;
      attitudes and beliefs about varenicline, previous experiences using varenicline, potential&#xD;
      challenges with adhering to varenicline, and similarly to explore experiences with past quit&#xD;
      attempts and barriers (individual, social, structural) to quitting.&#xD;
&#xD;
      The focus groups will follow written guides. In addition to pre-specified domains drawn from&#xD;
      the research questions above, the group facilitator will also listen for and explore emergent&#xD;
      topics. Focus groups will be audio-recorded and two research assistants will take notes&#xD;
      during each group discussion. All audio recordings will be transcribed verbatim, and&#xD;
      transcripts will be supplemented with notes taken during the focus group to ensure accuracy.&#xD;
      These transcripts will be analyzed for both pre-determined and emergent themes.&#xD;
&#xD;
      PHASE 2: PRE TEST Prior to starting the RCT the investigators will pre-test the intervention&#xD;
      components (ARM 3) to assess study design issues that may emerge, including those associated&#xD;
      with contacting subjects via cell phone, participant capacity to view text messages, timing&#xD;
      and content of text messaging, and use of the eCAPs system. Ten patients will be enrolled for&#xD;
      this phase with a target sample of 6 at end-of-treatment. Quantitative data collection,&#xD;
      described below, will follow. The investigators will also conduct post-intervention in-depth&#xD;
      interviews with all enrolled subjects to obtain feedback on the components' utility,&#xD;
      acceptability, and safety. The research team and consultants will meet after this pilot test&#xD;
      to make adjustments to the intervention components prior to the RCT.&#xD;
&#xD;
      PHASE 3: PILOT RCT Overview. This phase of research will compare three smoking cessation&#xD;
      interventions that were tested and refined in Phases 1 and 2. A total of 190 PLWHA who are&#xD;
      patients at CCC will be screened for this phase with a target sample of 150 at&#xD;
      end-of-treatment. The investigators will use a randomized controlled trial design. This is&#xD;
      not a formal efficacy trial but a test of the interventions feasibility, safety, and&#xD;
      acceptability. Additionally the study will provide preliminary evidence of efficacy of the&#xD;
      intervention components with respect to the study's main endpoints: a) adherence to&#xD;
      varenicline and b) smoking abstinence at 12 and 24 weeks. This data will inform the design of&#xD;
      a larger R01.&#xD;
&#xD;
      Intervention conditions ARM 1: Standard Care (SC). All CCC patients are screened for tobacco&#xD;
      use during their routine visits and offered a referral to the New York State (NYS) Quitline.&#xD;
      As part of current standard care, all trial participants will receive a self-help information&#xD;
      sheet, tailored to HIV+ smokers with frequently asked questions about using varenicline, and&#xD;
      a wallet card with the State Quitline number. All subjects will be offered varenicline for 12&#xD;
      weeks. All study participants will be asked whether they prefer to receive phone calls and&#xD;
      text messages from the study staff via their own phone or a phone provided by the study, at&#xD;
      no cost to the participant. If they choose the latter option, they will be given a pre-paid&#xD;
      cell phone for 3 months. Subjects in the SC arm will receive phones to facilitate their&#xD;
      ability to call the Quitline for assistance and to enable us to send follow-up appointment&#xD;
      reminders via text message. Each pre-paid phone will have an allowance of 200 minutes and&#xD;
      unlimited text messages per month. The investigators will instruct participants to use their&#xD;
      minutes only toward tobacco treatment or study related purposes. The investigators will track&#xD;
      minutes used and if minutes are used out, the investigators will add just enough minutes when&#xD;
      they need to contact the subject.&#xD;
&#xD;
      Varenicline therapy: All patients enrolled in the study will be given a 12-week supply of&#xD;
      varenicline. The dose will be 0.5 mg/day for 3 days followed by 0.5 mg BID for the next 4&#xD;
      days, and 1 mg BID after first 7 days. The research assistant will explain the use of the&#xD;
      medication, review potential side effects, and provide each subject with a wallet size&#xD;
      instruction card that will have the dosing schedule and information on how to use the&#xD;
      medication. Subjects will receive the medication at a follow-up study visit one week after&#xD;
      they are consented. Subjects will receive a three-week supply of varenicline and return at&#xD;
      week 4 of the study (timed from the first week they receive the medication). At the week 4&#xD;
      visit they will receive another 4 weeks of medication and will be asked to return at week 8&#xD;
      to receive the final 4 weeks of medication. More than one eCAP bottle will be distributed,&#xD;
      depending on the dose of medication and the week of treatment.&#xD;
&#xD;
      ARM 2: SC + Text messages (TxT). Subjects randomized to this arm will receive SC plus twice&#xD;
      daily text messaging to remind them to take their medication. Participants will begin&#xD;
      receiving text messages the day before they start taking medication, and text messaging will&#xD;
      continue for 12 weeks. The text messages are designed to convey relevant information to the&#xD;
      subjects while permitting a protective ambiguity. For example, none of the messages&#xD;
      transmitted to participants will use the terms HIV or AIDS. In addition, each text message&#xD;
      will have the tag &quot;ACT&quot; (Adherence to Cessation Treatment) indicating that it is coming from&#xD;
      the study. Participants will receive one medication adherence reminder message and one&#xD;
      motivational message regarding tobacco cessation each day. RTI staff will monitor the&#xD;
      delivery of the text messages. If participants do not receive text messages for two&#xD;
      consecutive days, the study research assistant will call them to assess reasons for message&#xD;
      failure. During the study, participants may opt out of receiving any category of messages by&#xD;
      contacting the study research assistants and informing him/her of their request. Requests to&#xD;
      decline a specific message type or to fully withdraw from the study will be handled promptly&#xD;
      and subjects will stop receiving messages within 48 hours of submitting their request to the&#xD;
      study research assistant. The investigators will use both symbols and text to accommodate low&#xD;
      literacy levels.&#xD;
&#xD;
      ARM 3: SC + TxT + adherence-focused motivational and behavioral therapy (ABT). In addition to&#xD;
      SC and TxT, the behavioral intervention group will receive seven proactive&#xD;
      cell-phone-delivered counseling sessions over a 6-week period. Drs. Shelley and Krebs have&#xD;
      adapted the telephone counseling manual that was developed and tested by Dr. Sherman which&#xD;
      was based on Dr. David Kalman's &quot;Treatment Manual for Extended Counseling to Treat Tobacco&#xD;
      Addiction,&quot;. The draft manual will be reviewed by Drs. Sherman, Wolfe, and Morgenstern and&#xD;
      then revised prior to the Phase 2 pretest. The research team will meet again to further&#xD;
      revise the manual based on findings from the Phase 2 post-intervention qualitative&#xD;
      interviews. The content of the manual combines the principles of Cognitive Behavioral Therapy&#xD;
      (CBT) with Motivational Interviewing (MI) techniques, both of which have been applied to&#xD;
      smoking cessation with promising results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End-of-intervention Varenicline Adherence</measure>
    <time_frame>4 Weeks</time_frame>
    <description>number of participants who took at least 80% prescribed dose since last interview, based on pill count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-of-intervention Smoking Abstinence</measure>
    <time_frame>7 Days</time_frame>
    <description>number of participants who achieved smoking abstinence based on self-reported 7-day point prevalence smoking abstinence verified by a carbon monoxide (CO) &lt; 8 ppm</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Tobacco Use Cessation</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will receive varenicline for smoking cessation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care + Text message</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care + Text Message + ABT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline will be provided for three months.</description>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_label>Standard Care + Text Message + ABT</arm_group_label>
    <arm_group_label>Standard Care + Text message</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Text Message</intervention_name>
    <description>Text messages will be developed twice daily for three months</description>
    <arm_group_label>Standard Care + Text Message + ABT</arm_group_label>
    <arm_group_label>Standard Care + Text message</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Adherence Behavioral Therapy</intervention_name>
    <description>Seven Adherence Behavioral Therapy sessions will given over a three month period</description>
    <arm_group_label>Standard Care + Text Message + ABT</arm_group_label>
    <other_name>ABT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Current patient at one of two SLR CCC clinics with a designated physician (had intake&#xD;
             visit and enrolled into clinic)&#xD;
&#xD;
          2. Age 18 years or older;&#xD;
&#xD;
          3. Current or regular smoker (&gt;5 cigarettes per day);&#xD;
&#xD;
          4. Carbon Monoxide (CO) monitor reading of &gt;8 ppm;&#xD;
&#xD;
          5. Willingness to set a quit date;&#xD;
&#xD;
          6. Able to conduct activities in English;&#xD;
&#xD;
          7. Ability to provide informed consent;&#xD;
&#xD;
          8. Willingness to carry/use a cell phone; AND&#xD;
&#xD;
          9. Eligible to take varenicline as determined by the patient's primary care provider&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable cardiovascular disease (e.g. uncontrolled blood pressure, unstable angina, or&#xD;
             myocardial infarction in the past 4 weeks);&#xD;
&#xD;
          2. Current homicidal or suicidal ideation, history of suicidal ideation, or history of&#xD;
             psychosis;&#xD;
&#xD;
          3. Has a serious or untreated psychiatric illness (major depression, bipolar or&#xD;
             schizophrenia);&#xD;
&#xD;
          4. Severe renal impairment (defined as having a creatinine clearance &lt; 30mL/min);&#xD;
&#xD;
          5. Currently using smokeless tobacco;&#xD;
&#xD;
          6. Currently using FDA-approved smoking cessation medication or other smoking cessation&#xD;
             treatment and or participating in another smoking cessation program;&#xD;
&#xD;
          7. Active drug use identified by a score of 6 or above on DAST-10 Drug Abuse Screening&#xD;
             Test;&#xD;
&#xD;
          8. Alcohol dependence or risk drinking identified by a score of 5 or above for men and 4&#xD;
             or above for women on AUDIT-C Alcohol Use Disorders Identification Test&#xD;
&#xD;
          9. Pregnant or nursing; AND/OR&#xD;
&#xD;
         10. Has a cognitive impairment that would preclude giving consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Shelley, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spencer Cox Center for Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>August 5, 2016</results_first_submitted>
  <results_first_submitted_qc>July 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2017</results_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Care</title>
          <description>Participants in this arm will receive varenicline for smoking cessation.&#xD;
Varenicline: Varenicline will be provided for three months.</description>
        </group>
        <group group_id="P2">
          <title>Standard Care + Text Message</title>
          <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months</description>
        </group>
        <group group_id="P3">
          <title>Standard Care + Text Message + ABT</title>
          <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months&#xD;
Adherence Behavioral Therapy: Seven Adherence Behavioral Therapy sessions will given over a three month period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Varenicline Adherence</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Smoking Abstinence</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not have good measurements</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Care</title>
          <description>Participants in this arm will receive varenicline for smoking cessation.&#xD;
Varenicline: Varenicline will be provided for three months.</description>
        </group>
        <group group_id="B2">
          <title>Standard Care + Text Message</title>
          <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months</description>
        </group>
        <group group_id="B3">
          <title>Standard Care + Text Message + ABT</title>
          <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months&#xD;
Adherence Behavioral Therapy: Seven Adherence Behavioral Therapy sessions will given over a three month period</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.64" spread="10.77"/>
                    <measurement group_id="B2" value="46" spread="9.96"/>
                    <measurement group_id="B3" value="47.88" spread="8.69"/>
                    <measurement group_id="B4" value="46.84" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>End-of-intervention Varenicline Adherence</title>
        <description>number of participants who took at least 80% prescribed dose since last interview, based on pill count</description>
        <time_frame>4 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Care</title>
            <description>Participants in this arm will receive varenicline for smoking cessation.&#xD;
Varenicline: Varenicline will be provided for three months.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care + Text Message</title>
            <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months</description>
          </group>
          <group group_id="O3">
            <title>Standard Care + Text Message + ABT</title>
            <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months&#xD;
Adherence Behavioral Therapy: Seven Adherence Behavioral Therapy sessions will given over a three month period</description>
          </group>
        </group_list>
        <measure>
          <title>End-of-intervention Varenicline Adherence</title>
          <description>number of participants who took at least 80% prescribed dose since last interview, based on pill count</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-of-intervention Smoking Abstinence</title>
        <description>number of participants who achieved smoking abstinence based on self-reported 7-day point prevalence smoking abstinence verified by a carbon monoxide (CO) &lt; 8 ppm</description>
        <time_frame>7 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Care</title>
            <description>Participants in this arm will receive varenicline for smoking cessation.&#xD;
Varenicline: Varenicline will be provided for three months.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care + Text Message</title>
            <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months</description>
          </group>
          <group group_id="O3">
            <title>Standard Care + Text Message + ABT</title>
            <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months&#xD;
Adherence Behavioral Therapy: Seven Adherence Behavioral Therapy sessions will given over a three month period</description>
          </group>
        </group_list>
        <measure>
          <title>End-of-intervention Smoking Abstinence</title>
          <description>number of participants who achieved smoking abstinence based on self-reported 7-day point prevalence smoking abstinence verified by a carbon monoxide (CO) &lt; 8 ppm</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Care</title>
          <description>Participants in this arm will receive varenicline for smoking cessation.&#xD;
Varenicline: Varenicline will be provided for three months.</description>
        </group>
        <group group_id="E2">
          <title>Standard Care + Text Message</title>
          <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months</description>
        </group>
        <group group_id="E3">
          <title>Standard Care + Text Message + ABT</title>
          <description>Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions&#xD;
Varenicline: Varenicline will be provided for three months.&#xD;
Text Message: Text messages will be developed twice daily for three months&#xD;
Adherence Behavioral Therapy: Seven Adherence Behavioral Therapy sessions will given over a three month period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Changes in appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vivd dreams or nightmares</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Problem with sleeping</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Leg Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Skin Peeling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Donna Shelley, MD, MPH/ Vice Chair for Research; Associate Professor of Population Health and Medici</name_or_title>
      <organization>Department of Population Health, New York University School of Medicine</organization>
      <phone>646-501-2526</phone>
      <email>Donna.Shelley@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

